Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21628419 | 0.97 | HDAC6 (0.42) | HDAC6HDAC1HDAC3HDAC2PTGER4 | |
| SCHEMBL21628538 | 0.92 | HDAC6 (0.44) | HDAC6HDAC1HDAC3HDAC2PTGER4 | |
| SCHEMBL21628534 | 0.90 | SMN1; SMN2 (0.42) | PTGER4 | |
| SCHEMBL21628802 | 0.87 | HDAC6 (0.44) | HDAC6HDAC1HDAC3HDAC2PTGER4 | |
| SCHEMBL21628543 | 0.87 | PTGER4 (0.43) | PTGER4 | |
| SCHEMBL21628896 | 0.87 | HDAC1 (0.49) | HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL21628547 | 0.87 | HPGD (0.43) | PTGER4 | |
| SCHEMBL21628570 | 0.87 | LMNA (0.46) | PTGER4 | |
| SCHEMBL21628610 | 0.86 | SMN1; SMN2 (0.39) | PTGER4 | |
| SCHEMBL21628740 | 0.84 | HDAC6 (0.50) | HDAC6HDAC1HDAC3HDAC2PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600696-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2026-04-14 | — | — | US | disclosed |
| US-20230406814-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2023-12-21 | — | — | US | disclosed |
| US-20230150923-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2023-05-18 | — | — | US | disclosed |
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-11591289-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2023-02-28 | — | — | US | disclosed |
| US-20220348535-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2022-11-03 | — | — | US | disclosed |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2021-04-15 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | Xeniopro GmbH (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150923-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | HDAC6 2604/4885HDAC1 1840/4885HDAC3 1743/4885 |
| US-20220348535-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | HDAC6 2604/4885HDAC1 1840/4885HDAC3 1743/4885 |
| US-11591289-B2 | Aromatic compounds | AHR, TYR, MUSK | HDAC6 2978/4885HDAC1 2387/4885HDAC3 2037/4885 |
| US-20210107863-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | HDAC6 2604/4885HDAC1 1840/4885HDAC3 1743/4885 |
| US-12600696-B2 | Aromatic compounds | CCR1, CCRL2, AHR | HDAC6 1293/4885HDAC1 315/4885HDAC3 102/4885 |
| US-20230406814-A2 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | HDAC6 2604/4885HDAC1 1840/4885HDAC3 1743/4885 |
| US-20200031763-A1 | NOVEL AROMATIC COMPOUNDS | AHR, TYR, MUSK | HDAC6 2604/4885HDAC1 1840/4885HDAC3 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.